Agios Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AGIO Nasdaq 8731 https://www.agios.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agios Pharmaceuticals Inc

Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago - Jan 15th, 2023 1:56 pm
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases - Jan 9th, 2023 1:00 am
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer - Jan 3rd, 2023 10:57 pm
3 Under-the-Radar Biotech Stocks to Buy in 2022 - Dec 24th, 2022 3:07 pm
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 - Dec 21st, 2022 1:00 pm
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition - Dec 12th, 2022 12:00 am
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition - Dec 10th, 2022 11:30 pm
Agios Appoints Tsveta Milanova as Chief Commercial Officer - Dec 6th, 2022 12:00 pm
Agios to Participate in December Investor Conference - Nov 30th, 2022 1:00 pm
The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup - Nov 17th, 2022 10:52 am
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients - Nov 11th, 2022 4:03 pm
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients - Nov 10th, 2022 9:01 pm
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%? - Nov 9th, 2022 10:36 am
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss - Nov 4th, 2022 4:20 pm
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition - Nov 3rd, 2022 1:00 pm
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates - Nov 3rd, 2022 12:25 pm
Edited Transcript of AGIO.OQ earnings conference call or presentation 3-Nov-22 12:00pm GMT - Nov 3rd, 2022 12:00 pm
Agios Reports Business Highlights and Third Quarter 2022 Financial Results - Nov 3rd, 2022 11:00 am
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty - Oct 27th, 2022 8:01 pm
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022 - Oct 20th, 2022 11:00 am